Table 2 Cancer related information of patients with solid tumors.
ChAdOx1 (N = 223) | Ad26.CoV2.S (N = 13) | mRNA-1273 (N = 40) | BNT162b2 (N = 333) | Overall (N = 609) | |
|---|---|---|---|---|---|
Treatment at first dose administration | |||||
Chemotherapy | 129 (57.8%) | 11 (84.6%) | 30 (75.0%) | 188 (56.5%) | 358 (58.8%) |
Immunotherapy | 35 (15.7%) | 0 (0.0%) | 4 (10.0%) | 36 (10.8%) | 75 (12.3%) |
Targeted/Hormonal therapy | 59 (26.5%) | 2 (15.4%) | 6 (15.0%) | 109 (32.7%) | 176 (28.9%) |
Primary tumor | |||||
Brain | 7 (3.1%) | 2 (15.4%) | 1 (2.5%) | 9 (2.7%) | 19 (3.1%) |
Head/neck | 6 (2.7%) | 1 (7.7%) | 1 (2.5%) | 12 (3.6%) | 20 (3.3%) |
Breast | 87 (39.0%) | 6 (46.2%) | 15 (37.5%) | 146 (43.8%) | 254 (41.7%) |
Lung | 13 (5.8%) | 0 (0.0%) | 1 (2.5%) | 17 (5.1%) | 31 (5.1%) |
Upper gastrointestinal | 21 (9.4%) | 0 (0.0%) | 7 (17.5%) | 35 (10.5%) | 63 (10.3%) |
Lower gastrointestinal | 26 (11.7%) | 2 (15.4%) | 8 (20.0%) | 53 (15.9%) | 89 (14.6%) |
Gynaecological | 13 (5.8%) | 2 (15.4%) | 1 (2.5%) | 21 (6.3%) | 37 (6.1%) |
Urological | 23 (10.3%) | 0 (0.0%) | 3 (7.5%) | 14 (4.2%) | 40 (6.6%) |
Skin | 11 (4.9%) | 0 (0.0%) | 2 (5.0%) | 12 (3.6%) | 25 (4.1%) |
Multiple | 5 (2.4%) | 0 (0.0%) | 0 (0.0%) | 1 (0.3%) | 6 (1.0%) |
Other | 11 (4.9%) | 0 (0.0%) | 1 (2.5%) | 13 (3.9%) | 25 (4.1%) |
Metastases | |||||
Absent | 112 (50.2%) | 9 (69.2%) | 14 (35.0%) | 155 (46.5%) | 290 (47.6%) |
Present | 111 (49.8%) | 4 (30.8%) | 26 (65.0%) | 178 (53.5%) | 319 (52.4%) |
